What alternative treatments are available for adenomyosis in a woman who cannot or does not wish to use dienogest?

Treatment Alternatives to Dienogest for Adenomyosis

For women who cannot or will not use dienogest, the levonorgestrel-releasing intrauterine system (LNG-IUS) is the most effective first-line alternative medical therapy, with uterine artery embolization (UAE) as the preferred procedural option for those failing medical management.

Medical Management Alternatives

First-Line: Levonorgestrel-Releasing Intrauterine System (LNG-IUS)

The LNG-IUS stands out as the superior first-line alternative due to several key advantages 1:

• Local mechanism of action with lower systemic hormone exposure
• Long duration of action after placement (up to 5 years)
• User independence - no daily compliance required
• Contraceptive benefit included
• Recent randomized controlled trial demonstrated significant improvement in both pain and bleeding in women with adenomyosis, superior to combined oral contraceptives 1

Second-Line Medical Options

When LNG-IUS is not suitable or fails:

Oral Progestins:

• Drospirenone (4 mg) - effectively manages heavy menstrual bleeding and dysmenorrhea 2
• Desogestrel (75 mcg) - improves symptoms but has higher discontinuation rates due to reduced long-term efficacy 2
• Norethisterone acetate - useful as second-line when other progestins fail 2

Combined Oral Contraceptives:

• Effective for pain relief and bleeding control compared to placebo 3
• May be equivalent to more costly regimens 3
• Less effective than progestin-only options in head-to-head comparisons 1

GnRH Agonists:

• Highly effective for at least 3 months of therapy 3
• Should be considered second-line therapy due to hypogonadal effects 4
• Add-back therapy is essential - reduces or eliminates bone mineral loss without reducing pain relief efficacy 3
• Limited by side effects for long-term use

Oral GnRH Antagonist Combinations:

• Pooled analysis shows effectiveness not decreased by concomitant adenomyosis 1
• Emerging option requiring more data

Procedural/Interventional Alternatives

Uterine Artery Embolization (UAE)

UAE is the most established procedural alternative for adenomyosis when medical therapy fails 5:

Efficacy:

• Long-term symptomatic relief (median 27.9 months follow-up): 65-82% for pure adenomyosis or adenomyosis with fibroids 5
• More recent studies (24-65 months follow-up): 73-88% symptom control 5
• Prospective study showed 83% complete adenomyosis necrosis with significant symptom relief 5

Important Considerations:

• Recurrence rates at 2 years: approximately 40-50% 5
• Long-term data (up to 7 years) shows sustained improvement in most patients 1
• 7-18% hysterectomy rate for persistent symptoms 1
• Pregnancy is possible after UAE - counsel patients accordingly 1
• Particularly effective when fibroids coexist with adenomyosis 1

Other Ablative Procedures

Recent evidence supports additional minimally invasive options 6:

Radiofrequency Ablation (RFA):

• Proven effective in reducing abnormal uterine bleeding and dysmenorrhea
• Associated with decreased uterine volume
• Low rates of symptom recurrence and reintervention

High-Intensity Focused Ultrasound (HIFU):

• Non-invasive option
• Effective for symptom reduction
• Limited availability in the US

Percutaneous Microwave Ablation (PMWA):

• Emerging option with promising results
• Limited data available

Critical Caveat: Access to ablative therapies in the USA is limited and primarily off-label due to lack of FDA approval 6.

Surgical Options

Adenomyomectomy (Cytoreductive Surgery)

• Highly effective for abnormal uterine bleeding and pelvic pain 7
• Reduces uterine volume significantly
• Should only be performed by experienced surgeons in dedicated centers 7
• Carries post-operative risks and potential obstetric complications
• Consider for focal adenomyosis when fertility preservation is critical

Hysterectomy

• Definitive treatment providing complete resolution 1
• Allows simultaneous treatment of concomitant conditions (endometriosis, high-risk cervical dysplasia) 1
• Should be avoided if less invasive procedures are available 1
• Associated with long-term risks: cardiovascular disease, osteoporosis, dementia, especially when performed at young age 1
• If performed, use least invasive route (vaginal > laparoscopic > abdominal) 1

Treatment Algorithm

Step 1: Trial LNG-IUS as first-line medical therapy

• If contraindicated or refused → oral progestins (drospirenone or desogestrel)

Step 2: If medical therapy fails after 6-12 months:

• Consider GnRH agonist with add-back therapy for 3-6 months
• Evaluate for procedural intervention

Step 3: For persistent symptoms despite medical management:

• UAE is preferred procedural option for most patients
• Consider RFA or HIFU if available
• Adenomyomectomy only in specialized centers for focal disease

Step 4: Hysterectomy reserved for:

• Failure of all conservative measures
• Patient preference after thorough counseling
• Concomitant conditions requiring definitive surgery

Key Clinical Pearls

Combination therapy may be more effective than monotherapy 6 - consider sequential or concurrent approaches.

Avoid common pitfalls:

• Don't use GnRH agonists without add-back therapy long-term
• Don't perform adenomyomectomy without appropriate surgical expertise
• Don't rush to hysterectomy without exhausting conservative options
• Remember that endometrial ablation has high failure rates with adenomyosis 1

Patient selection matters: Those with more severe baseline symptoms may benefit most from treatment but also face higher recurrence risk 8, 9.